EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study (Q27851683)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study	scientific article

Statements

scholarly article

1 reference

13 November 2016

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study (English)

1 reference

13 November 2016

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Maciej Krzakowski

object named as

Maciej Krzakowski

4

0 references

object named as

Rodryg Ramlau

5

0 references

author name string

Robert Pirker

1

0 references

Jose R Pereira

2

0 references

Joachim von Pawel

3

0 references

Keunchil Park

6

0 references

Filippo de Marinis

7

0 references

Wilfried E E Eberhardt

8

0 references

Luis Paz-Ares

9

0 references

Stephan Störkel

10

0 references

Karl-Maria Schumacher

11

0 references

Anja von Heydebreck

12

0 references

Ilhan Celik

13

0 references

Kenneth J O'Byrne

14

0 references

publication date

January 2012

0 references

Lancet Oncology Commission

0 references

13

0 references

1

0 references

33-42

0 references

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970318-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970318-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeted therapies: Biomarkers in NSCLC for selecting cetuximab therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970318-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970318-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970318-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970318-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: Comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970318-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970318-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Patterns of treatment effects in subsets of patients in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970318-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of treatment-effect heterogeneity using biomarkers measured on a continuous scale: subpopulation treatment effect pattern plot.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970318-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Estimators of the Mantel-Haenszel variance consistent in both sparse data and large-strata limiting models

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970318-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970318-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970318-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970318-7

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR inhibitor enhances cisplatin sensitivity of oral squamous cell carcinoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970318-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970318-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970318-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970318-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970318-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970318-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970318-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970318-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970318-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatme

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970318-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970318-7

7 January 2021

based on heuristic

inferred from DOI database lookup

HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970318-7

7 January 2021

based on heuristic

inferred from DOI database lookup

HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970318-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(11)70318-7

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27851683&oldid=1965418464"